Friday, February 24, 2012

New Approvals and filings in Japan

  • Nichi-Iko and Pfizer Japan receives approval for marketing generic cisplatin for the indication of Biliary Tract cancer
  • Lilly receives approval for Zyprexa for Bipolar disorrder
  • Ajinomoto Pharma files NDA for AJG522, as a bowel cleansing agent
  • CMIC Holdings has filed a new drug application (NDA) for its urea cycle disorder (UCD) treatment sodium phenylbutyrate (CMK-304), which has been designated as an orphan drug